Target Engagement and Pharmacodynamic Biomarker Analysis Following Treatment with the Oral Gut Targeted HIF 1 α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis
Target Engagement and Pharmacodynamic Biomarker Analysis Following Treatment with the Oral Gut Targeted HIF 1 α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis
ECCO – July 2021
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
